Measuring and targeting aldosterone and renin in atherosclerosis-A review of clinical data

作者：Hillaert Marieke A; Lentjes Eef G; Beygui Farzin; Kemperman Hans; Asselbergs Folkert W; Nathoe Hendrik M; Agostoni Pierfrancesco; Voskuil Michiel; Ivanes Fabrice; Jude Brigitte; Bertrand Michel E; Pasterkamp Gerard; van der Graaf Yolanda; Doevendans Pieter A; Montalescot Gilles; Van Belle Eric^*

来源：American Heart Journal, 2011, 162(4): 585-596.

DOI：10.1016/j.ahj.2011.06.015

Our understanding of the development and progression of atherosclerosis has increased substantially over the past decades. A significant role for the renin-angiotensin-aldosterone system (RAAS) in this process has gained appreciation in recent years. Preclinical and clinical studies have associated components of the RAAS with various cardiovascular disease conditions. Classically known for its contribution to hypertension, dysregulation of the system is now also believed to promote vascular inflammation, fibrosis, remodeling, and endothelial dysfunction, all intimately related to atherosclerosis.
The reduction in cardiovascular mortality and morbidity, as seen with the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, supports the concept that RAAS is involved in the pathogenesis of atherosclerotic disease. However, the underlying molecular mechanisms of the pathophysiology remain to be completely understood. Evidence points toward additional benefit from therapeutic approaches aiming at more complete inhibition of the system and the possible utility of renin or aldosterone in the prediction of cardiovascular outcome.
This review will summarize the current knowledge from clinical studies regarding the presumptive role of renin and aldosterone in the prediction and management of patients with atherosclerosis. For this purpose, a literature search was performed, focusing on available clinical data regarding renin or aldosterone and cardiovascular outcome. (Am Heart J 2011;162:585-96.)

• 出版日期2011-10